Abstract:
Die vorliegende Erfindung beschreibt ein Verfahren zur Reinigung von durch Addition von Alkylenoxid an Alkylenglykol erhaltene Polyalkylenglykole, wobei nach erfolgter Addition das erhaltene Polyalkylenglykol bei einem pH-Wert von > 7 mit einem Bleichmittel aus der Gruppe der Peroxide, Persäuren, Percarbonate, Perborate, Peroxidsulfate oder Sauerstoff, jeweils gegebenenfalls unter Zusatz eines Bleichaktivators behandelt wird.Das Verfahren eignet sich insbesondere zur Herstellung von Polyethylenglykol mit Molgewichten von 196 bis 203 g/mol, das Arzneibuchanforderungen erfüllt.
Abstract:
The invention relates to a method for purifying polyalkylene glycols obtained by adding alkylene oxide to alkylene glycol, whereby after addition, the polyalkylene glycol is treated at a pH value of > 7 with a bleaching agent from the group consisting of peroxide, peracids, percarbonates, perborates, peroxide sulfates or oxygen, optionally using a bleach activator. The method is particularly useful for the production of polyethylene glycol with molecular weights ranging from 196 to 203 g/mol, complying with pharmacopoeial requirements.
Abstract:
A process for purifying alkoxylated fats by treatment with a solid substance, characterized in that the solid substance used is a mixture of aluminium oxide and a silicate.
Abstract:
The invention relates to a method for purifying polyalkylene glycols obtained by adding alkylene oxide to alkylene glycol, whereby after addition, the polyalkylene glycol is treated at a pH value of > 7 with a bleaching agent from the group consisting of peroxide, peracids, percarbonates, perborates, peroxide sulfates or oxygen, optionally using a bleach activator. The method is particularly useful for the production of polyethylene glycol with molecular weights ranging from 196 to 203 g/mol, complying with pharmacopoeial requirements.
Abstract:
A process for purifying alkoxylated fats by treatment with a solid substance, characterized in that the solid substance used is a mixture of aluminium oxide and a silicate.
Abstract:
Medicament for oral administration which contains as active substance per individual dose, besides the customary galenic auxiliaries, 10 to 1000 mg of a compound of general formula (I) or (II) in which W is a carbonyl group or a single bond, R1 is a hydrogen atom or a group of the general formula R3CO in which R3 is a lower alkyl, lower alkoxy, mono lower alkylamino or di lower alkylamino group, R2 is an alkyl residue with 3 to 20 carbon atoms which may be branched or unbranched and contain 1 to 3 double bonds, a saturated cycle of 3 to 7 carbon atoms integrated into the chain or as substituent, or may be substituted by one or more aromatic rings or contain an oxygen or sulphur atom, as a racemate and as isolated enantiomers; or the addition salt thereof with a physiologically acceptable acid, and the active substances themselves insofar as they are novel.